Organogenesis Holdings Inc. (ORGO) Stock Forecast
ORGO analyst forecast
as of October 17, 2026- Analyst consensus
- Hold 3.00 / 5 from 2 analysts
- Price target
- $2.00 average of analyst targets
- Upside to target
- +100.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.17
- 52-week range
- $1.00 – $6.54
ORGO analyst ratings
2 analystsNumber of analysts at each rating.
ORGO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ORGO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.17 | $0.18 | −195.8% | 1 |
| Current fiscal year (2026) | −$1.38 | −$1.38 | −$1.37 | $0.42 | −424.5% | 2 |
| Next fiscal year (2027) | −$0.31 | −$0.39 | −$0.23 | −$1.38 | +77.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ORGO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $52.1M | $51.6M | $52.6M | −65.5% | 2 |
| Current fiscal year (2026) | $196.1M | $191.5M | $200.6M | −65.2% | 2 |
| Next fiscal year (2027) | $269.7M | $240.1M | $299.3M | +37.5% | 2 |
ORGO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ORGO revenue: reported and forecast
ORGO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.12 | −$0.12 | −$0.17 | +41.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.74 | −$0.82 | −$0.82 | −$0.82 | −$1.38 | +85.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.23 | −$0.28 | −$0.28 | −$0.28 | −$0.31 | +34.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ORGO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ORGO beat in 7 of 12.
What analysts expect from ORGO
2 analysts cover Organogenesis; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.00, 100.0% above the latest close of $1.00. Analysts expect earnings of −$1.38 per share for 2026, −424.5% from a year earlier. For 2027 the average estimate is −$0.31 per share on revenue of $269.7 million. Organogenesis beat the EPS estimate in 7 of the last 12 quarters.
Related: ORGO income statement, ORGO key metrics, ORGO chart. See the ORGO stock overview for the latest quote and news.
ORGO forecast FAQ
What is Organogenesis's price target?
The average analyst price target for Organogenesis is $2.00, 100.0% above the latest close of $1.00.
Is Organogenesis a buy, hold or sell?
Of 2 analysts covering Organogenesis, 0 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Organogenesis's EPS forecast?
Analysts forecast −$1.38 per share for 2026 (range −$1.38 to −$1.37); for 2027 the estimate is −$0.31.
What is Organogenesis's revenue forecast?
The average revenue estimate for 2026 is $196.1 million, growth of −65.2%; for 2027 it is $269.7 million.
When does Organogenesis report earnings?
Organogenesis is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.17.
Does Organogenesis usually beat earnings estimates?
Organogenesis reported EPS at or above the analyst estimate in 7 of the last 12 quarters.